Products for the treatment of hemophilia A and B prepared by ion exchange chromatography
Affiliations
- PMID: 8177717
Item in Clipboard
Products for the treatment of hemophilia A and B prepared by ion exchange chromatography
Nouv Rev Fr Hematol (1978).
1994.
Abstract
In France, since 1988, factor VIII concentrate are prepared by ion exchanged chromatography from plasma cryoprecipitate. The final product is a very high purity factor VIII with a specific activity (SA) between 150 and 250 IU/mg of proteins. Viral inactivation is obtained after solvent detergent method with TNBP and Tween 80. Since 1989 hemophilia B patients are treated with a factor IX preparation purified from a prothrombin complex concentrate and after solvent detergent inactivation. Factor IX concentrate is a high purity product with a SA of 50 to 100 U/mg of protein.
Similar articles
-
Recombinant factor VIII in hemophilia A: the Canadian experience.Blood Coagul Fibrinolysis. 1997 Aug;8 Suppl 1:S33-9. Blood Coagul Fibrinolysis. 1997. PMID: 9351535 Review.
-
Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.Thromb Haemost. 1995 Mar;73(3):553-5. Thromb Haemost. 1995. PMID: 7667845 No abstract available.
-
Inactivation and clearance of viruses during the manufacture of high purity factor IX.Biologicals. 2000 Sep;28(3):129-36. doi: 10.1006/biol.1999.0242. Biologicals. 2000. PMID: 10964439
-
Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.Thromb Haemost. 1999 Aug;82(2):531-9. Thromb Haemost. 1999. PMID: 10605747 Review. No abstract available.
-
Substitution treatment of hemophilia a and b.Schweiz Med Wochenschr. 1975 Jun 14;105(24):783-4. Schweiz Med Wochenschr. 1975. PMID: 1145162 English.
MeSH terms
Substances
LinkOut - more resources
Medical